Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06604832 · ClinicalTrials.gov registry record · Phase 1
Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture
A Phase 1 study, sponsored by Kalpna Kay Durairaj, MD, FACS.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT06604832: Completed Phase 1 study, sponsored by Kalpna Kay Durairaj, MD, FACS.
NCT06604832 is a Phase 1 study that has completed, run by Kalpna Kay Durairaj, MD, FACS. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06604832, a Phase 1 study, has completed, sponsored by Kalpna Kay Durairaj, MD, FACS.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The goal of this split-face clinical trial is to test the efficacy of microtox in improving facial skin quality, fine wrinkles, and texture. Participants will: * be randomly assigned to Group A (which will receive 20 units of neuromodulator on the left side of the forehead and a placebo saline treatment on the right side) or Group B (which will receive 20 units of neuromodulator on the left side of the forehead and 20 units of a different neuromodulator brand on the right side as a comparator) * have one treatment session at week 0, and two live assessment visits at weeks 2 and 12 * have their pictures taken at each visit to track progress
Primary Outcome
The treating physician and the blinded, secondary evaluator will rate the subject after the final treatment. The scale identifies 6 parameters of skin quality: (1) loss of elasticity, (2) wrinkles, (3) roughness, (4) pigmentation/lentigines, (5) erythema, and (6) pore size. The scale has 5 points to describe the intensity of parameters 1-5: 0 implies none, 1 implies mild, 2 implies moderate, 3 implies severe, and 4 implies very severe. For parameter 6, 0 implies fine, 1 implies small, 2 implies
Interventions
- DRUG PrabotulinumtoxinA-Xvfs
- DRUG IncobotulinumtoxinA
- DRUG saline solution (placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-09-03 |
| Est. Completion | 2025-09-16 |
| Phase | Phase 1 |
What the finished NCT06604832 record still lists
NCT06604832 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 3 interventions - of which PrabotulinumtoxinA-Xvfs is the first listed.
NCT06604832 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06604832 about?
NCT06604832 is a clinical study titled "Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture". The goal of this split-face clinical trial is to test the efficacy of microtox in improving facial skin quality, fine wrinkles, and texture. Participants will: * be randomly assigned to Group A (which will receive 20 units of neuromodulator on the left side of the forehead and a placebo saline trea...
What is the current status of trial NCT06604832?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-09-03. Estimated completion is 2025-09-16.
What interventions are being tested in trial NCT06604832?
The interventions under investigation include: PrabotulinumtoxinA-Xvfs (DRUG), IncobotulinumtoxinA (DRUG), saline solution (placebo) (DRUG).
Who is sponsoring clinical trial NCT06604832?
This trial is sponsored by Kalpna Kay Durairaj, MD, FACS, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06604832's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI